Canada - English - Health Canada

fresenius kabi canada ltd - cisplatin - solution - 1mg - cisplatin 1mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin for injection is indicated for the treatment of advanced testicular cancer. cisplatin for injection is indicated for the treatment of advanced ovarian cancer. cisplatin for injection is indicated for the treatment of advanced bladder cancer. cisplatin for injection is contraindicated in patients with severe hypersensitivity to cisplatin [see warnings and precautions (5.4)] . risk summary based on human data from published literature, cisplatin for injection can cause fetal harm when administered to pregnant women. advise pregnant women and females of reproductive potential of the potential risk to a fetus. data demonstrates transplacental transfer of cisplatin. exposure of pregnant women to cisplatin-containing chemotherapy has been associated with oligohydramnios, intrauterine growth restriction, and preterm birth. cases of neonatal acute respiratory distress syndrome, cytopenias, and hearing loss have been reported. cisplatin for injection administration to animals during and after organogenesi

Canada - English - Health Canada

hikma canada limited - cisplatin - solution - 1mg - cisplatin 1mg

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection - excipient ingredients: water for injections; sodium chloride; sodium hydroxide; mannitol - cisplatin can destroy cells in your body that may cause certain types of cancer (tumour of testis, tumour of ovary, tumour of the bladder, head and neck epithelial tumour, lung cancer and for cervical cancer in combination with radiotherapy).

Ireland - English - HPRA (Health Products Regulatory Authority)

hospira uk limited - cisplatin - concentrate for soln for inf - 1 mg/ml - platinum compounds

Ireland - English - HPRA (Health Products Regulatory Authority)

caduceus pharma ltd - cisplatin - concentrate for soln for inf - 1 mg/ml - platinum compounds

Ireland - English - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - cisplatin - concentrate for soln for inf - 0.5 micromol

Ireland - English - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - cisplatin - concentrate for soln for inf - 1 micromol

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cisplatin - concentrate for soln for inf - 1 mg/ml - platinum compounds

United Kingdom - English - myHealthbox

cipla (eu) limited - cisplatin. - concentrate for solution for infusion - 1mg/ml - other antineoplastic agents, pla - for the treatment of: • advanced or metastatic testicular cancer • advanced or metastatic ovarian cancer • advanced or metastatic bladder carcinoma • advanced or metastatic squamous cell carcinoma of the head and neck • advanced or metastatic non-small cell lung carcinoma • advanced or metastatic small cell lung carcinoma